We empower people with innovative treatment solutions

 

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 

 

Development pipeline targeting large medical needs

 

 

AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products

Key News

SEPTEMBER 18, 2023
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

SEPTEMBER 5, 2023
Orexo to present at Pareto Securities 14th Annual Healthcare Conference

To read all NEWS go to Media in the top menu 

Key financial figures

Group net revenue

634 MSEK
Last Twelve Months, Q322-Q223

Group EBITDA

-121 MSEK
Last Twelve Months, Q322-Q223

US Pharma segment EBIT

293 MSEK
Last Twelve Months, Q322-Q223

Cash position

251 MSEK
Q223

News Flow

Regulatory Press Releases

To read all NEWS go to Media in the top menu